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Absract
Parasites are responsible for a wide variety of infectious diseases causing an enormous health and economical
blight. Malaria is one such prominent disease that causes widespread infections in humans and results in
innumerable deaths annually. The development of resistance of the malarial parasites to the conventional drugs
has signaled for an urgent need to design new drugs in an effective way and also to identify and study new drug
targets to combat this disease. The rational design of a drug is usually based on the biochemical and
physiological differences between the pathogen and the host. So in this current study we focus on the
striking differences in the purine metabolism of the malarial parasite Plasmodium falciparum and that of the
host. Based on this, we submit a hypothesis on targeting a protein Adenosine deaminase that plays an important role
in the purine metabolism of the parasite. In this study a synthetic and a natural drug were used and their efficacy
was compared and analyzed.
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Background
Malaria (from medieval Italian: mala aria – bad air) formerly called as ague or marsh fever is an infectious
disease that causes about 350-500million infections in humans and 1-3million deaths annually. This infectious
disease is widespread in many tropical, subtropical regions and mostly prevalent among young children in Sub
Saharan Africa [1]. Malaria is caused by a protozoa Plasmodium (Phylum Apicomplexa). In humans malaria is
caused by P. falciparum, P. malariae, P. ovale, P. vivax, and P. knowlesi [2][3]. Among the Plasmodium
protozoa, Plasmodium falciparum is responsible for about 80% infections and 90% deaths [4]. The parasite’s
primary hosts and transmission vectors are female mosquitoes of the genus Anopheles and humans act as intermediates.
The parasite is relatively protected from attack by the body’s immune system because for most of its human
life cycle it resides within the liver and blood cells and is relatively invisible to immune surveillance. Even
though circulating infected blood cells are destroyed in the spleen, the Plasmodium falciparum, to avoid this
fate displays adhesive proteins on the surface of the infected blood cells to stick to the walls of small blood
cells, thereby sequestering the parasite from passing through the general circulation and spleen. Although the
RBC surface adhesive proteins (PfEMP1) are exposed to the immune system, they do not serve as good
immune targets because of their extreme diversity and there are at least 60 different variations of PfEMP1 within
a single parasite and limitless variations within parasite population [5]. To compound these problems malarial
parasites have become more and more resistant to conventional treatment and drugs.
The present study is about a novel method of drug designing and identifying a drug target based on the
differences in the purine pathway of the parasite and host. Unlike their mammalian host most parasites lack
the pathways for de novo purine biosysnthesis and rely on the salvage pathway to meet their purine demands [6].
In some cases there are sufficient distinctions between corresponding enzymes of the purine salvage pathway of
the host and the parasite and that may be effectively utilized to design specific inhibitors or targets to
design antimalarial drugs. Interestingly the first step in the purine salvage pathway differ significantly between
the malarial parasites and host. In the malarial parasites, purines formed as products of polyamine synthesis
are recycled in a novel pathway in which methyl thioinosine is generated by Adenosine deaminase The
enzyme Plasmodium falciparum purine nucleoside phosphorylase converts both 5′- methyl thioinosine and inosine
to hypoxanthine and activates the purine pathway that plays an important role in the life cycle of the malarial
parasite [6]. We submit an hypothesis on targeting and blocking the protein Adenosine deaminase that will inturn
stop the purine pathway of the parasite and may prove to be an effective step in controlling and combating malaria.
Methodology
The sequence of the target protein Adenosine deaminase was obtained from NCBI database [7] and the
Protein Data Bank (PDB) [8] was used for obtaining the 3D structure of the desired protein. The tool BLAST was
used for searching and finding the correct template homologue of the target sequence [9]. Information about
the domain region, region of alignment and function of the domain of the protein was retrieved from Pfam [10].

Homology Modeling:
A bioinformatics tool MODELLER was used for homology modeling of protein 3D structure [11]. A
template protein of known 3D structure with enough sequence similarity to the target protein Adenosine
deaminase was selected and both the sequences were aligned. Using the alignments the coordinates of the
matching residues in the known structure were copied to the unknown protein and the resulting model was
evaluated using Combinatorial Extension [12], ProQ server [13] and Ramachandran plot [14].
Ligands (drugs) used for targeting the desired protein were drawn using the tool ACD Chemsketch [15].
The sketched structure was then converted to 3D format and optimized to ascertain if the structure obtained was
an accurate format to favour docking. Inorder to proceed with the docking studies, the secondary structure of
the protein was retrieved from RCSB software through which the active sites, the ligand binding sites and
metal binding sites were carefully analyzed. Using another software called WEBLAB [16] hydrogen coordinates
were added and docked with the drugs used in this study namely Primaquine (synthetic drug) and Quinine
(natural drug). The process of docking was done using a software called GOLD that docks each ligand 10times
with the target protein and gives the best result of them.
Results and Discussion
The protein sequence of Adenosine deaminase was retrieved from the target base of NCBI and the
template selection was done using PHI-PSI-BLAST based on criterias like, the hit should have the same
function, show maximum alignment with the target sequence and the alignment should have less number of gaps.
The hit score obtained was 64% which can be considered as a suitable template. A suitable homology model was
built using the software MODELLER to retrieve the 3D structure of the target protein that was given as input.
The minimum energy level (1790.0635) obtained was the best and the 3D structure was viewed with the help
of RASMOL.
The built model was evaluated using Combinatorial Extension (CE), ProQ server and Ramachandran
plot. Combinatorial Extension is a database for 3D protein structure comparison and alignment and was used to
find out the superimposition of the template and the model. ProQ is a neutral network based predictor and was used
to predict the quality of the protein model. Two quality measures LG score and MAX sub were used. Any
score greater than 4 was supposed to be a good quality model with regard to LG score and scores greater than 0.5
with regard to MAX sub. The scores obtained for the built model were 6.173 (LG score) and 0.676 (MAX
sub). Evaluation of the model using Ramachandran plot showed that the number of residues present in the
favoured region is 86.97%, allowed region is 10.76% and outside region is 0.85% . Among the two drugs under
study, quinine was found to have an greater GOLD score (43.53) than primaquine (28.86) during docking. Also
when the formation of hydrogen bonds between the drugs and their respective targets were studied it showed that
the hydroden bond distance between quinine and Adenosine deaminase was 1.979, whereas there was no
hydrogen bond established between primaquine and Adenosine deaminase.
Utility
A pioneering approach of merging Bioinformatics and pharmaceutics has been carried out in this hypothesis
to study the mechanism of action of drugs in treating life threatening infections like malaria and arrive at a
long lasting, safe and effective solution. Keeping in mind the amount of resistance that malarial parasites
have developed against conventional drugs, we have proposed a new method of drug designing and
target identification based on the purine pathway of the malarial parasite and we have also compared the efficacy of
a natural drug against the conventional synthetic drug in treating malaria. We believe this approach will go a long
way in helping researches all over the world to find a effective and permanent solution in
eradicating
malaria.
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